Cyclo Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q4, Cyclo Therapeutics's (NASDAQ:CYTH) reported sales totaled $585.12 thousand. Despite a 27.66% increase in earnings, the company posted a loss of $2.79 million.
Benzinga ·
Benzinga
